Blastic Plasmacytoid Dendritic Cell Neoplasm

This is a rare and serious type of cancer that starts in the bone marrow. It comes from a type of white blood cell called a plasmacytoid dendritic cell. It can affect the blood, bone marrow, lymph nodes, spleen, and sometimes the brain or skin. It's often called a 'Blastic NK Cell Lymphoma' or 'Blastic NK-Cell Lymphoma'.

Condition

What people with Blastic Plasmacytoid Dendritic Cell Neoplasm report

Every report comes from a Lived member, sent anonymously.

Have you had Stem Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm?

NameHow it went

About Blastic Plasmacytoid Dendritic Cell Neoplasm

What It Is

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive blood cancer. It starts in immature forms of plasmacytoid dendritic cells, immune cells that normally help the body respond to viral infections. It accounts for fewer than 1 in 100 blood cancers. Most people first notice changes in the skin: dark purple, brown or bruise-like patches, raised plaques or firm lumps, often on the head, upper body or arms. They are usually painless, which is one reason they can be mistaken for bruises or a harmless rash. The disease frequently also involves the bone marrow, blood and lymph nodes, and sometimes the spleen, liver or the fluid around the brain and spinal cord. Less often, there are no skin changes and the disease is found because of low blood counts, swollen lymph nodes or general symptoms. BPDCN has had several older names, including CD4+/CD56+ hematodermic neoplasm and blastic natural killer (NK) cell lymphoma, because the cell it comes from was unclear for years. It is now recognized as its own disease, distinct from acute myeloid leukemia (AML), and that distinction matters because the treatments differ.

Causes & Risk Factors

The cause of BPDCN is not known, and no environmental exposure, inherited trait or lifestyle factor has been shown to raise the risk. The cancer cells carry genetic changes, but these are acquired during a person's life rather than passed down in families, and they are not something a person can test for in advance or prevent. BPDCN is most common in older adults, with a typical age at diagnosis in the mid-60s to early 70s, and it affects men two to five times as often as women. It can also occur in children and younger adults. In at least 1 in 10 people, BPDCN appears before, alongside or after another disorder of the bone marrow, such as myelodysplastic syndrome (MDS, in which the marrow makes abnormal, poorly working blood cells), chronic myelomonocytic leukemia (CMML) or AML. The two conditions often arise from the same abnormal cell line.

How It's Diagnosed

Because the skin lesions can resemble bruises, other rashes or other cancers, BPDCN is usually diagnosed from a skin biopsy. A pathologist examines the sample and stains the cells for proteins on their surface, called markers. BPDCN cells typically carry CD123 (a receptor that is also the target of treatment) together with CD4, CD56 and other markers typical of plasmacytoid dendritic cells, while lacking the markers of T cells, B cells and myeloid cells. This pattern separates BPDCN from AML that has spread to the skin, its most important look-alike. Because the disease is rare and the testing is specialized, review by a hematopathologist (a doctor who diagnoses blood cancers from tissue) experienced with BPDCN is important. Once the diagnosis is made, further tests show how far the disease has spread. These usually include blood counts and other blood tests, a bone marrow biopsy, and imaging such as CT or PET-CT scans to check lymph nodes and organs. Testing the spinal fluid with a lumbar puncture (spinal tap) is often considered, because in some studies cancer cells were found there in about half of people tested, including people with no nervous system symptoms.

Treatment Options

BPDCN is treated with therapy that reaches the whole body, even when the cancer seems limited to the skin. Without it, skin-only disease eventually spreads into the blood and marrow. Because the disease is rare, care at a cancer center with experience in BPDCN and access to clinical trials is recommended where possible. Tagraxofusp (Elzonris) is the only medicine approved by the FDA specifically for BPDCN, for adults and children 2 years and older. It is a targeted drug: a protein that latches onto the CD123 receptor on BPDCN cells and delivers a toxin that kills them. It is given as a short intravenous (IV) infusion once a day for five days, in cycles every three weeks. In studies of people treated with it first, most responded and over half went into complete remission, meaning no detectable disease on testing. Its main risk is capillary leak syndrome, in which fluid and protein seep out of small blood vessels into the tissues; it can be life-threatening if not caught and treated early. Because it nearly always happens in the first cycle, that cycle is given in the hospital with daily weights and blood tests, and later cycles can often be given as an outpatient. Changes in liver tests and infusion reactions are also common early on. Intensive chemotherapy, using combinations developed for acute leukemia or lymphoma, is the other established option, mainly for people fit enough to tolerate it. Regimens designed for acute lymphoblastic leukemia appear to work best, although no regimen has been compared head to head in a trial. In older adults, chemotherapy brings remission in about half of people and carries a high risk of serious complications. For people who reach remission and are fit enough, an allogeneic stem cell transplant (replacing the blood-forming system with stem cells from a donor) offers the best chance of long-term control and is recommended in first remission. It is an intensive treatment with significant risks of its own, and many older people are not candidates. After transplant, chemotherapy given into the spinal fluid is recommended to lower the chance of the cancer returning in the brain and spinal cord. Newer approaches are being studied in clinical trials. These include adding azacitidine and venetoclax (Venclexta), medicines already used together for some older adults with AML, to tagraxofusp, and pivekimab sunirine, an investigational antibody-drug conjugate that also targets CD123.

What to Expect

BPDCN usually responds to initial treatment, but it has a strong tendency to come back, and cancer that returns is much harder to control. Outlook depends heavily on age, overall health and whether a transplant is possible. Studies have reported median survival ranging from about 9 months to a little over 2 years, much of it from the era before newer treatments. People who reach remission and go on to a donor transplant do best; in one large report about half were alive five years after transplant. Children tend to respond better and relapse less often than adults. These figures describe groups and cannot predict one person's course. Treatment is demanding. The first cycle of tagraxofusp, or a course of intensive chemotherapy, usually means a hospital stay, followed by frequent clinic visits for infusions and blood tests. A transplant brings its own long recovery and close follow-up. Skin lesions often fade more slowly than disease in the blood or marrow, and some leave lasting discoloration that does not necessarily mean the cancer is still active. After treatment, regular check-ups with blood tests, skin exams and sometimes marrow biopsies look for signs of relapse, including in the nervous system, where BPDCN more often returns.

When to Seek Help

Have new purple, brown or bruise-like skin patches, plaques or lumps checked by a doctor if they appear without an injury and do not fade, or keep spreading, especially alongside swollen lymph nodes. A biopsy is the only way to tell BPDCN apart from more common skin problems. During tagraxofusp treatment, contact your care team right away for rapid weight gain, new or worsening swelling of the legs, hands or face, lightheadedness, or shortness of breath, since these can be early signs of capillary leak syndrome. Severe trouble breathing or fainting needs emergency care. After treatment, tell your care team promptly about new skin lesions, new nervous system symptoms such as persistent headache, numbness or weakness, or new swollen lymph nodes, which can be signs that the disease has returned.

Questions to Ask Your Doctor

  1. 1.Has the diagnosis been confirmed with the full set of BPDCN markers, and has the disease been found in my marrow, lymph nodes or spinal fluid?
  2. 2.Should my first treatment be tagraxofusp, chemotherapy or a clinical trial, and why?
  3. 3.Am I a candidate for a donor stem cell transplant, and what would it involve for me?
  4. 4.How will we watch for capillary leak syndrome and other side effects, and what should I check for at home?
  5. 5.What will follow-up look like after treatment, and how will we watch for the disease returning?

Last reviewed • Oct 2026

Educational content, not medical advice.